This trial is testing a new drug, pemigatinib, to see if it can help treat acute myeloid leukemia (AML). AML is a type of cancer that starts in the bone marrow (the soft tissue inside bones where blood cells are made). Pemigatinib works by inhibiting (blocking) a protein called FGFR (fibroblast growth factor receptor). This protein is involved in the growth of leukemia cells.
1 Primary · 8 Secondary · Reporting Duration: Date of first response (>= immune complete remission) till date of documented relapse assessed up to 2 years from last dose of study intervention
Experimental Treatment
32 Total Participants · 1 Treatment Group
Primary Treatment: Pemigatinib · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: